Human papillomavirus vaccine introduction - the first five years

Vaccine

Volumn 30, Issue SUPPL.5, 2012, Pages

  Markowitz, Lauri E ^a   Tsu, Vivien ^b   Deeks, Shelley L ^c   Cubie, Heather ^d   Wang, Susan A ^e   Vicari, Andrea S ^f   Brotherton, Julia M L ^g  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b PATH   (United States)

^c PUBLIC HEALTH ONTARIO   (Canada)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f Pan American Health Organization   (Costa Rica)

^g VICTORIAN CYTOLOGY SERVICE   (Australia)

Author keywords

HPV; Vaccine acceptability; Vaccine introduction

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE; WART VIRUS VACCINE;

AUSTRALIA; BHUTAN; BUDGET; CANADA; CLINICAL EVALUATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG MONITORING; DRUG SAFETY; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH CENTER; HEALTH PROGRAM; HUMAN; INCOME; INTERPERSONAL COMMUNICATION; LOWEST INCOME GROUP; MALAYSIA; PERU; PREVENTIVE HEALTH SERVICE; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RWANDA; SCHOOL HEALTH SERVICE; UGANDA; UNITED KINGDOM; UNITED STATES; VACCINATION; VIET NAM;

EID: 84876251944     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.05.039     Document Type: Review

References (95)

1. Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer 2006;118:3030-44.
2. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;56:1-24.
3. Lindley MC, Smith PJ, Rodewald LE. Vaccination coverage among U.S. adolescents aged 13-17 years eligible for the Vaccines for Children program, 2009. Public Health Rep 2011;126(Suppl 2):124-34.
4. CDC. National and state vaccination coverage among adolescents aged 13 through 17- United States, 2010. MMWR 2011; 60:1117-23.
5. Charo RA. Politics, parents, and prophylaxis-mandating HPV vaccination in the United States. N Engl J Med 2007;356:1905-8.
6. Colgrove J. The ethics and politics of compulsory HPV vaccination. N Eng J Med 2006;355:2389-91.
7. CDC. Recommendations on the Use of Quadrivalent Human Papillomavirus Vaccine in Males - Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 2011;60:1705-8.
8. Recommendations on a Human Papillomavirus Immunization Program. Available at: http://www.phac-aspc.gc.ca/publicat/2008/papillomaviruspapillome/papillomavirus-papillome-12-eng.php (last accessed May 2012).
9. HPV vaccination programs in Canada; Are we hitting the mark? Avaialble at: http://www.canceradvocacy.ca/reportcard/2008/HPV%20Vaccination%20Programs%20in%20Canada.pdf (last accessed May 2012).
10. Publicly funded immunization programs in Canada - Routine schedule for infants and children including special programs and catch-up programs (as of December 2011). Available at: http://www.phac-aspc.gc.ca/im/ptimprogprogimpt/table-1-eng.php (last accessed May 2012).
11. Immunise Australia Program. Human papillomavirus (HPV). Available at: http://www.health.gov.au/internet/immunise/publishing.nsf/Content/immunise-hpv#register (last accessed May 2012).
12. Brotherton J, Gertig D, Chappell G, Rowlands L, Saville M. Catching up with the catch-up: HPV vaccination coverage data for Australian women aged 18-26 years from the National HPV Vaccination Program Register. Commun Dis Intell 2011;35:197-201.
13. Dorleans F, Giambi C, Dematte L, Cotter S, Stefanoff P, Mereckiene J, et al. The current state of introduction of human papillomavirus vaccination into national immunisation schedules in Europe: first results of the VENICE2 2010 survey. Euro Surveill 2010:15.
14. Bonanni P, Levi M, Latham NB, Bechini A, Tiscione E, Lai P, et al. An overview on the implementation of HPV vaccination in Europe. Hum Vaccin 2011;7: 128-35.
15. Sander BB, Rebolj M, Valentiner-Branth P, Lynge E. Introduction of human papillomavirus vaccination in Nordic countries. Vaccine 2012;30:1425-33.
16. Annual HPV vaccine coverage in England in 2009/2010. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH123795 (last accessed May 2012).
17. National Services Scotland. HPV Immunisation Uptake Statistics. Available at: http://www.isdscotland.org/Health-Topics/Child-Health/Publications/2011-09-22/2011-09-22-ImmunisationHPV-Report.pdf?60303896666. (last accessed May 2012).
18. Haut Conseil de la santé publique - Avis relatif à la vaccination contre les infections à papillomavirus humains des jeunes filles âgées de 14 à 23 ans (French). Available at: http://www.hcsp.fr/docspdf/avisrapports/hcspa20101217ppmvjf1423.pdf. (last accessed May 2012).
19. Fagot JP, Boutrelle A, Ricordeau P, Weill A, Allemand H. HPV vaccination in France: uptake, costs and issues for the National Health Insurance. Vaccine 2011;29:3610-6.
20. Cancer: Le Gardasil, un vacin a l'effet boomerang. October 10, 2011. Available at: http://www.20minutes.fr/sante/802652-cancer-gardasil-vaccineffet-boomerang (last accessed May 2012).
21. Widgren K, Simonsen J, Valentiner-Branth P, Molbak K. Uptake of the human papillomavirus-vaccination within the free-of-charge childhood vaccination programme in Denmark. Vaccine 2011;29:9663-7.
22. Simoens C, Sabbe M, Van Damme P, Beutels P, Arbyn M. Introduction of human papillomavirus (HPV) vaccination in Belgium, 2007-2008. Euro Surveill 2009:14.
23. Limia A, Pachon I. Coverage of human papillomavirus vaccination during the first year of its introduction in Spain. Euro Surveill 2011:16.
24. Kane M, Serrano B, de Sanjose S, Wittet S. Implementation of HPV immunization in the developing world. Vaccine 2012;30(S5):F192-200.
25. Human papillomavirus vaccines. WHO position paper. Wkly Epidemiol Rec 2009;84:118-31.
26. GAVI Alliance. Accelerated vaccine introduction initiative. Available at: http://www.gavialliance.org/about/gavis-business-model/avi/(last accessed May 2012).
27. Arie S. How should GAVI build on its success? BMJ 2011;343:d5182.
28. GAVI Alliance. GAVI takes first steps to introduce vaccines against cervical cancer and rubella. Available at: http://www.gavialliance.org/library/news/press-releases/2011/gavi-takes-first-steps-to-introduce-vaccines-againstcervical-cancer-and-rubella/(last accessed May 2012).
29. PAHO. PAHO Revolving Fund: Vaccine and Syringe Prices, 2011. Immunization Newsletter 2011;33(1):4-5. Available at: http://new.paho.org/hq/index.php?option=comdocman&task=docdownload&gid=14893&Itemid=358 (last accessed July 2012).
30. LaMontagne DS, Barge S, Thi Le N, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. Bull World Health Organ 2011;89: 821-30B.
31. Tsu VD, LaMontagne DS, Mendoza Araujo MA, Seruyange R, Mugisha E, Ramos Chavez I. Think big, start small: shaping an HPV vaccination strategy. In: Presented at the 27th International Papillomavirus Conference. 2011.
32. HPV vaccination in Africa: lessons learned from a pilot program in Uganda. Available at: http://www.rho.org/files/PATH HPV lessonslearnedUganda2011.pdf (last accessed May 2012).
33. Singh Y, Shah A, Singh M, Verma S, Shrestha BM, Vaidya P, et al. Human papilloma virus vaccination in Nepal: an initial experience in Nepal. Asian Pac J Cancer Prev 2010;11:615-7.
34. Gardasil Access Program. Available at: http://gardasilaccessprogram.com/section/141 (last accessed May 2012).
35. Centers for Disease Control and Prevention (CDC). Progress toward implementation of human papillomavirus vaccination-the Americas, 2006-2010. MMWR Morb Mortal Wkly Rep 2011;60:1382-4.
36. Financing HPV vaccination in developing countries. Lancet 2011;377:60622-3.
37. Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngaboa F. Achieving high coverage in Rwanda's national human papillomavirus vaccination programme. Bull WHO 2012 (published online May 23, 2012).
38. Vaccine donations; WHO-UNICEF joint statement. Available at: http://whqlibdoc.who.int/hq/2010/WHOIVB10.09eng.pdf (last accessed May 2012).
39. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009;27:7270-81.
40. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-7.
41. Reports of health concerns following HPV vaccination. Available at: http://www.cdc.gov/vaccinesafety/vaccines/hpv/gardasil.html (last accessed May 2012).
42. Gardasil (human papillomavirus vaccine). Available at: http://www.tga.gov.au/safety/alerts-medicine-gardasil-070624.htm (last accessed May 2012).
43. MHRA's second year saftey review of the human pappillomavirus immunisation programme. Available at: http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specificinformationandadvice/Product-specificinformationandadvice-G-L/HumanpapillomavirusHPVvaccine/CON023340 (last accessed May 2012).
44. Vaccine in pregnancy surveillance (Available at: http://www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/VaccineInPregnancySurveillance (last accessed May 2012).
45. Dana A, Buchanan KM, Goss MA, Seminack MM, Shields KE, Korn S, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009;114:1170-8.
46. Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011;29:8279-84.
47. Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012;271:193-203.
48. World Health Organization. Global Advisory Committee on Vaccine Safety, report of meeting held 17-18 June 2009. Available at: http://www.who.int/vaccinesafety/Jun2009/en/index.html (last accessed May 2012).
49. Institute of Medicine. Adverse Effects of Vaccines: Evidence and Causality. Available at: http://www.iom.edu/Reports/2011/Adverse-Effects-of-Vaccines-Evidence-and-Causality (last accessed May 2012).
50. Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010;59:626-9.
51. Watson M, Shaw D, Molchanoff L, McInnes C. Challenges, lessons learned and results following the implementation of a human papilloma virus school vaccination program in South Australia. Aust N Z J Public Health 2009;33:365-70.
52. Lifesitenews.com. Two European deaths thought to be associated with HPV vaccine. Available at; http://www.lifesitenews.com/news/archive/ldn/2008/jan/08012809 (last accessed May 2012).
53. Cancer vaccine girl died of malignant chest tumor. Medical News Today 2009. Available at: http://www.medicalnewstoday.com/articles/165961.php (last accessed May 2012).
54. EMA statement on the safety of Gardasil. Available at: http://www.ema.europa.eu/humandocs/PDFs/EPAR/gardasil/Gardasilpress release.pdf (last accessed May 2012).
55. Bonanni P, Cohet C, Kjaer SK, Latham NB, Lambert PH, Reisinger K, et al. A summary of the post-licensure surveillance initiatives for GARDASIL/SILGARD. Vaccine 2010;28:4719-30.
56. Lehtinen M, Apter D, Dubin G, Kosunen E, Isaksson R, Korpivaara EL, et al. Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing. Int J STD AIDS 2006;17:517-21.
57. Markowitz LE, Hariri S, Unger ER, Saraiya M, Datta SD, Dunne EF. Post-licensure monitoring of HPV vaccine in the United States. Vaccine 2010;28:4731-7.
58. Donovan B, Franklin N, Guy R, Grulich AE, Regan DG, Ali H, et al. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11:39-44.
59. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, Gertig DM. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-92.
60. Donovan B. A national program with a national impact: quadrivalent HPV vaccination and genital warts in Australia, 2004-2010. In: ISSTDR Quebec City, Canada; 2011.
61. Monitoring the coverage and impact of human papillomavirus vaccine - report of WHO meeting, November 2009. Wkly Epidemiol Rec 2010;85:237-43.
62. Ogilvie G, Anderson M, Marra F, McNeil S, Pielak K, Dawar M, et al. A populationbased evaluation of a publicly funded, school-based HPV vaccine program in British Columbia, Canada: parental factors associated with HPV vaccine receipt. PLoS Med 2010;7:e1000270.
63. Dorell CG, Yankey D, Santibanez TA, Markowitz LE. Human papillomavirus vaccination series initiation and completion, National Immunization Survey-Teen, 2008-2009. Pediatrics 2011;128:830-9.
64. Brewer NT, Gottlieb SL, Reiter PL, McRee AL, Liddon N, Markowitz L, et al. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. Sex Transm Dis 2011;38:197-204.
65. Allen JD, Othus MKD, Shelton RC, Li Y, Norman N, Tom L, et al. Parental decision making about the HPV vaccine. Cancer Epidemiol Biomarkers Prev 2010;19:2187-98.
66. Caskey R, Lindau ST, Alexander GC. Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health 2009;45:453-62.
67. Dempsey AF, Abraham LM, Dalton V, Ruffin M. Understanding the reasons why mothers do or do not have their adolescent daughters vaccinated against human papillomavirus. Ann Epidemiol 2009;19:531-8.
68. Gottlieb SL, Brewer NT, Sternberg MR, Smith JS, Ziarnowski K, Liddon N, et al. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. J Adolesc Health 2009;45:430-7.
69. Kahn JA, Ding L, Huang B, Zimet GD, Rosenthal SL, Frazier AL. Mothers' intention for their daughters and themselves to receive the human papillomavirus vaccine: a national study of nurses. Pediatrics 2009;123:1439-45.
70. Bernat DH, Harpin SB, Eisenberg ME, Bearinger LH, Resnick MD. Parental support for the human papillomavirus vaccine. J Adolesc Health 2009;45:525-7.
71. Sotiriadis A, Dagklis T, Siamanta V, Chatzigeorgiou K, Agorastos T, The LSG. Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet 2012 Jan 14. [Epub ahead of print].
72. Jumaan A, Ghanem S, Taher J, Braikat M, Awaidy SA, Dbaibo GS. Prospects and challenges in the introduction of HPV vaccines in the MENA region. Vaccine, in press.
73. Schwartz JL. HPV vaccination's second act: promotion, competition, and compulsion. Am J Public Health 2010;100:1841-4.
74. Doren M, Gerhardus A, Gerlach FM, et al. [Scientists call for a reevaluation of HPV vaccination and an end to the misleading information]. Pharmazie in unserer Zeit 2009;38:186-7.
75. Ontario bishops message on HPV innoculation in Catholic schools. Available at: http://www.ccrl.ca/index.php?id=4881 (last accessed May 2012).
76. Mello MM, Abiola S, Colgrove J. Pharmaceutical companies' role in state vaccination policymaking: the case of human papillomavirus vaccination. Am J Public Health 2012;102:893-8.
77. Remark on HPV vaccine could ripple for years. Available at: http://www.nytimes.com/2011/09/20/health/20hpv.html (last accessed May 2012).
78. Gardasil and HPV infection. Available at: http://www.nvic.org (last accessed May 2012).
79. Our girls are not guinea pigs. Available at: www.macleans.ca/science/health/article.jsp?content=20070827108312108312 (last accessed May 2012).
80. Judicial Watch v. Food and Drug Administration (No. 07-1776) - Gardasil. Available at: http://www.judicialwatch.org/cases/judicial-watch-v-food-anddrug-administration-no-07-1776-gardasil (last accessed May 2012).
81. S.A.N.E. VAX, Inc. Available at: www.SANEVAX.org (last accessed May 2012).
82. Tomljenovic L, Shaw CA. Human papillomavirus (HPV) vaccine policy and evidence-based medicine: Are they at odds? Ann Med 2011 Dec 22. [Epub ahead of print].
83. Palefsky JM, Giuliano AR, Goldstone S, Moreira Jr ED, Aranda C, Jessen H, et al. HPV Vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-85.
84. November 2011 PBAC meeting outcomes. Available at: http://www.health.gov.au/internet/main/publishingnsf/Content/DF3D2BF61025D73CCA2579660080CA50/$File/PBAC%20Outcomes%20Nov%202011%20-%20Positive%20recommendations.pdf (last accessed May 2012).
85. CCDR. Update on human papillomavirus (HPV) vaccines. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/assets/pdf/acs-dcc-1-eng.pdf (last accessed May 2012).
86. Kreimer AR, Rodriguez AC, Hildesheim A, Herrero R, Porras C, Schiffman M, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011;103:1444-51.
87. Dobson S, Dawar M, Money D. Two dose vaccine trial of Q-HPV, results at 36 months. In: Presented at the 27th International Papillomavirus Conference. 2011.
88. Vaccination contre les HPV: passage du schéma à trois doses au schéma à deux doses chez les adolescentes âgées de moins de 15 ans. Available at: http://www.infovac.ch/index2.php?option=comdocman&task=docget&Itemid=1&id=718 (last accessed May 2012).
89. Zimmerman RK, Nowalk MP, Lin CJ, Fox DE, Ko FS, Wettick E, et al. Randomized trial of an alternate human papillomavirus vaccine administration schedule in college-aged women. J Womens Health 2010;19:1441-7.
90. Neuzil KM, Canh do G, Thiem VD, Janmohamed A, Huong VM, Tang Y, et al. Immunogenicity and reactogenicity of alternative schedules of HPV vaccine in Vietnam: a cluster randomized noninferiority trial. JAMA 2011;305:1424-31.
91. Vlaams Agentschap Zorg en Gezondheid. Available at: http://www.zorg-engezondheid.be/(last accessed May 2012).
92. Poljak M, Seme K, Maver PJ, Kocjana BJ, Cuschierib KS, Rogovskayac S, et al. Human papillomavirus prevalence and type distribution, cervical cancer screening practices and current status of vaccination implementation in central and eastern Europe. Vaccine, in press.
93. HPV vaccination coverage in New Zealand: closing equity gaps 2011. Available at: http://www.hpvtoday.com/webDocs/Eng/downloads/HPV/HPVToday23Eng.pdf (last accessed May 2012).
94. van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 2011;29:4601-7.
95. Velicer C. Post-licensure safety study of quadrivalent human papillomavirus vaccine among 189,629 females. In: Presented before the Advisory Committee on Immunization Practices. October 2011.